quoted from here
Human Medications, Human Drugs, Animal Medications, Animal Drugs, Pharmacy law, Pharmaceutical law, Compounding law, Sterile and Non Sterile Compounding 797 Compliance, Veterinary law, Veterinary Compounding Law; Health Care; Awareness of all Types of Compounding Issues; Pharmacy Benefit Managers (PBMs), Outsourcing Facilities Food and Drug Administration and Compliance Issues
Thursday, August 7, 2014
Due to the growing concern among veterinary oncologists, NSCS contracted a third-party analytics laboratory to conduct potency and sterility tests on random batches of all competing compounded L-Asparaginase. Using the FDA approved parent drug (Elspar®), the test results showed that the competing product's potency ranged between 48% to 53%. Whereas the NSCS / QmedRx product comparatively yielded a 96% potency test result (exceeding USP-797 guidelines).
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment